Abstract
Imidazoline I 1-receptors are present in the heart and may be involved in atrial natriuretic peptide (ANP) release. The following studies investigated whether moxonidine (an antihypertensive imidazoline I 1-receptor and α 2-adrenoceptor agonist) acts directly on the heart to stimulate ANP release, and to characterize the receptor type involved in this action. Perfusion of rat (200–225 g) isolated hearts with moxonidine (10 − 6 and 10 − 5 M), for 30 min, resulted in ANP release (83 ± 29 and 277 ± 70 ng/30 min, above basal, respectively), significantly ( P < 0.01) different from perfusion with buffer (− 6 ± 31 ng/30 min). ANP release stimulated by moxonidine (10 − 6 M) was inhibited by co-perfusion with the antagonists, AGN192403 (imidazoline I 1-receptor), phenoxybenzamine (α 2 > α 1-adrenoceptors), and prazosin (α 1 > α 2-adrenoceptors), but increased by rauwolscine (α 2-adrenoceptors). Perfusion with 10 − 5 M brimonidine (full α 2-adrenoceptor agonist) inhibited moxonidine-stimulated ANP release. Similarly, moxonidine (10 − 6 M) tended to reduce coronary flow, but significantly increased coronary flow in the presence of brimonidine, which was vasoconstrictive when perfused alone. Coronary flow was reduced by 10 − 5 M each, brimonidine > clonidine > moxonidine; while similar bradycardia was observed with clonidine and moxonidine, but not with brimonidine. In conclusion, these results argue in favor of moxonidine acting primarily on imidazoline I 1-receptors to release ANP, with both α 2-adrenoceptor and imidazoline I 1-receptors exerting inhibitory inter-relation. In contrast, the coronary vasodilatory effect of moxonidine requires full activation of α 2-adrenoceptor. The sympatholytic and ANP-releasing effects of moxonidine appear to be mediated by cardiac imidazoline receptors that may be differentially localized. Most importantly, moxonidine can stimulate ANP release from the heart without contribution of the central nervous system.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.